Anteris Technologies Global Corp. Files Registration Statement for Proposed US Initial Public Offering
24 Noviembre 2024 - 8:08PM
Business Wire
Anteris Technologies Global Corp. (“ATGC”) today announced that
it has filed a Registration Statement on Form S-1 with the U.S.
Securities and Exchange Commission (the “SEC”), relating to the
proposed initial public offering of its common stock (“Common
Stock”) in the U.S. (the “Offering”). All Common Stock to be sold
in the Offering will be offered by ATGC.
The amount of Common Stock to be offered and the price range for
the proposed Offering have not yet been determined. The Offering is
subject to market conditions and there can be no assurances as to
whether or when the Offering may be completed, or as to the actual
size, price or other terms of the Offering.
ATGC intends to list its Common Stock on the Nasdaq Global
Select Market under the symbol “AVR.”
Following the Offering, ATGC intends to list its CHESS
Depositary Interests (“CDIs”) (representing underlying shares of
Common Stock on a 1 CDI-for-1 share of Common Stock basis) on the
Australian Securities Exchange under the symbol “AVR.”
TD Cowen, Barclays and Cantor are acting as joint book-running
managers for the proposed Offering, with Lake Street Capital
Markets acting as lead manager.
The proposed Offering will be made only by means of a
prospectus. Once available, a copy of the preliminary prospectus
relating to the proposed Offering may be obtained from: TD
Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York
10017, by telephone at (855) 495-9846 or by e-mail at
TD.ECM_Prospectus@tdsecurities.com; Barclays, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue Edgewood, NY 11717, by
telephone at (888) 603-5847 or by e-mail at
Barclaysprospectus@broadridge.com; or Cantor, 110 East 59th Street,
6th Floor, New York, NY 10022, by telephone at (212) 915-1800 or by
e-mail at prospectus@cantor.com.
A registration statement relating to the Common Stock has been
filed with the SEC but has not yet become effective. The Common
Stock may not be sold, nor may offers to buy be accepted, prior to
the time the registration statement becomes effective.
This announcement is for informational purposes only and does
not constitute an offer to sell or the solicitation of an offer to
buy the Common Stock, and shall not constitute an offer,
solicitation or sale of the Common Stock in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
jurisdiction.
About ATGC
ATGC was incorporated on January 29, 2024 for the purpose of
reorganizing the operations of Anteris Technologies Ltd
(“Anteris”), an Australian public company originally registered in
Western Australia, Australia and listed on the Australian
Securities Exchange (“ASX”), into a structure whereby the ultimate
parent company will be a Delaware corporation.
About Anteris Technologies Ltd (ASX: AVR)
Anteris Technologies Ltd (ASX: AVR) is a structural heart
company committed to designing, developing, and commercialising
innovative medical devices. Founded in Australia, with a
significant presence in Minneapolis, USA (a MedTech hub), Anteris
is science-driven, with an experienced team of multidisciplinary
professionals delivering potentially transformative solutions to
structural heart disease patients.
Anteris’ lead product, DurAVR®, is a transcatheter heart valve
(THV) for treating aortic stenosis. It is the first transcatheter
aortic valve replacement (TAVR) to use a single piece of
bioengineered tissue. This biomimetic valve is uniquely shaped to
mimic the performance of a healthy human aortic valve.
DurAVR® THV is made using ADAPT® tissue, Anteris’ patented
anti-calcification tissue technology. ADAPT® tissue has been used
clinically for over 10 years and distributed for use in over 55,000
patients worldwide.
The ComASUR® Delivery System was designed to provide controlled
deployment and accurate placement of the DurAVR® THV with
balloon-expandable delivery, designed to achieve precise alignment
with the heart’s native commissures to achieve ideal valve
positioning.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241124424451/en/
For more information: Investor Relations
investors@anteristech.com Anteris Technologies Ltd +61 1300 550 310
| +61 7 3152 3200
Investor Relations (US) Malini Chatterjee, Ph.D.
Blueprint Life Science Group +1 917 330 4269
Avaron Mining (TSXV:AVR)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Avaron Mining (TSXV:AVR)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024